NCT01590979View on ClinicalTrials.gov

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

NATerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Atrial Fibrillation New OnsetHemorrhageProlonged QTc IntervalVentricular TachycardiaMedical Care; Complications, Late Effect of Complications
Interventions
DRUG

Ranolazine

1000mg, two times a day, 12 hour intervals

DRUG

Placebo

two times a day, 12 hour intervals

Trial Locations (1)

10305

Staten Island University Hosptial, Staten Island

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Northwell Health

OTHER

NCT01590979 - Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation | Biotech Hunter | Biotech Hunter